Gentile Pietro
1Department of Surgical Science, Plastic and Reconstructive Surgery, "Tor Vergata" University, Rome, 00133, Italy.
2Founder and Scientific Director of Academy of International Regenerative Medicine & Surgery Societies (AIRMESS), 1201 Geneva, Switzerland.
Aging Dis. 2021 Apr 1;12(2):330-344. doi: 10.14336/AD.2021.0121. eCollection 2021 Apr.
In this second return of the pandemic, January 2021, it appears to be clear that a Nano-sized organism, the SARS-CoV-2, has rendered the human race helpless, made the global health status decline, and drowned the world economy. However, it does not appear clear the real origin of the SARS-CoV-2 and the aim of this work is to report and discuss, maybe for the first time since the pandemic began, the scientific data published in this specific field, analyzing the potentially available weapons against the SARS-CoV-2. About this last point, a ray of hope comes from the potential of Mesenchymal Stem Cells (MSCs) that has already been established in Coronavirus Disease 2019 (COVID-19), and in particular from the Adipose-Derived Mesenchymal Stem Cells (AD-MSCs). However, cell-based therapy has its own limits, especially represented by the know-how in this field and by the rules of applications. It was suggested a biological therapy using AD-MSCs as a weapon against COVID-19, as they can be a game-changer owing to their immuno-modulatory nature, which combats the cytokine storm characterizing this disease, and their practical efficiency, which will realistically aid large access to therapy worldwide.
在2021年1月疫情的这第二轮反扑中,似乎很明显,一种纳米级别的生物体——严重急性呼吸综合征冠状病毒2(SARS-CoV-2),已使人类束手无策,导致全球健康状况下降,并拖累了世界经济。然而,SARS-CoV-2的真正起源似乎并不明确,而这项工作的目的是报告并讨论,也许是自疫情开始以来首次,该特定领域已发表的科学数据,分析针对SARS-CoV-2的潜在可用武器。关于最后这一点,一线希望来自间充质干细胞(MSCs)的潜力,这种潜力在2019冠状病毒病(COVID-19)中已经得到证实,尤其是来自脂肪来源的间充质干细胞(AD-MSCs)。然而,基于细胞的疗法有其自身的局限性,特别是体现在该领域的专业技术和应用规则方面。有人提出使用AD-MSCs作为对抗COVID-19的武器进行生物治疗,因为它们具有免疫调节特性,能够对抗该疾病特有的细胞因子风暴,且其实用效率能切实帮助在全球范围内实现大规模治疗,可能会带来改变局面的效果。